Traders sold shares of AbbVie Inc. (NYSE:ABBV) on strength during trading on Friday. $93.66 million flowed into the stock on the tick-up and $138.11 million flowed out of the stock on the tick-down, for a money net flow of $44.45 million out of the stock. Of all stocks tracked, AbbVie had the 0th highest net out-flow for the day. AbbVie traded up $1.71 for the day and closed at $95.95

Several equities analysts have weighed in on the company. Evercore ISI assumed coverage on AbbVie in a report on Wednesday, August 16th. They issued an “outperform” rating and a $95.00 price objective for the company. Leerink Swann set a $106.00 price objective on AbbVie and gave the company a “buy” rating in a report on Tuesday, December 5th. SunTrust Banks reaffirmed a “buy” rating and issued a $95.00 price objective on shares of AbbVie in a report on Wednesday, September 13th. UBS cut AbbVie from a “buy” rating to a “neutral” rating and boosted their price target for the stock from $79.00 to $92.00 in a report on Monday, September 25th. Finally, Argus boosted their price target on AbbVie from $90.00 to $110.00 and gave the stock a “buy” rating in a report on Friday, September 29th. Seven research analysts have rated the stock with a hold rating, eleven have given a buy rating and one has issued a strong buy rating to the stock. AbbVie currently has a consensus rating of “Buy” and an average price target of $97.96.

The firm has a market capitalization of $153,177.45, a PE ratio of 18.07, a price-to-earnings-growth ratio of 1.33 and a beta of 1.52. The company has a quick ratio of 1.32, a current ratio of 1.45 and a debt-to-equity ratio of 5.08.

AbbVie (NYSE:ABBV) last released its quarterly earnings results on Friday, October 27th. The company reported $1.41 EPS for the quarter, beating analysts’ consensus estimates of $1.39 by $0.02. AbbVie had a return on equity of 153.80% and a net margin of 24.38%. The firm had revenue of $7 billion for the quarter, compared to analyst estimates of $7 billion. During the same quarter in the previous year, the company posted $1.21 EPS. The business’s revenue was up 8.8% on a year-over-year basis. analysts forecast that AbbVie Inc. will post 5.55 earnings per share for the current year.

The business also recently declared a quarterly dividend, which will be paid on Thursday, February 15th. Shareholders of record on Friday, January 12th will be given a $0.71 dividend. This represents a $2.84 dividend on an annualized basis and a dividend yield of 2.96%. The ex-dividend date is Thursday, January 11th. This is a positive change from AbbVie’s previous quarterly dividend of $0.64. AbbVie’s payout ratio is 62.29%.

In related news, VP Robert A. Michael sold 6,699 shares of the company’s stock in a transaction dated Thursday, September 28th. The stock was sold at an average price of $88.00, for a total transaction of $589,512.00. Following the sale, the vice president now owns 10,007 shares in the company, valued at approximately $880,616. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Chairman Richard A. Gonzalez sold 218,193 shares of the company’s stock in a transaction dated Tuesday, November 21st. The shares were sold at an average price of $94.01, for a total value of $20,512,323.93. Following the sale, the chairman now owns 492,030 shares in the company, valued at approximately $46,255,740.30. The disclosure for this sale can be found here. Insiders sold a total of 277,125 shares of company stock worth $25,891,756 in the last quarter. Corporate insiders own 0.23% of the company’s stock.

Several hedge funds have recently added to or reduced their stakes in the company. Jennison Associates LLC purchased a new stake in AbbVie during the 3rd quarter valued at $544,418,000. Capital International Investors raised its stake in AbbVie by 137.7% during the 3rd quarter. Capital International Investors now owns 7,854,929 shares of the company’s stock valued at $697,989,000 after buying an additional 4,550,954 shares during the last quarter. Vanguard Group Inc. raised its stake in AbbVie by 3.3% during the 2nd quarter. Vanguard Group Inc. now owns 115,920,673 shares of the company’s stock valued at $8,405,409,000 after buying an additional 3,706,941 shares during the last quarter. Janus Henderson Group PLC raised its stake in AbbVie by 1,949.7% during the 2nd quarter. Janus Henderson Group PLC now owns 3,833,535 shares of the company’s stock valued at $277,967,000 after buying an additional 3,646,510 shares during the last quarter. Finally, Orbis Allan Gray Ltd raised its stake in AbbVie by 35.7% during the 2nd quarter. Orbis Allan Gray Ltd now owns 12,704,919 shares of the company’s stock valued at $921,233,000 after buying an additional 3,340,038 shares during the last quarter. Hedge funds and other institutional investors own 69.32% of the company’s stock.

ILLEGAL ACTIVITY WARNING: “Investors Sell AbbVie (ABBV) on Strength (ABBV)” was published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this piece on another website, it was copied illegally and republished in violation of United States and international trademark & copyright law. The original version of this piece can be accessed at https://www.thecerbatgem.com/2017/12/10/investors-sell-abbvie-abbv-on-strength-abbv.html.

AbbVie Company Profile

AbbVie Inc (AbbVie) is a research-based biopharmaceutical company. The Company is engaged in the discovery, development, manufacture and sale of a range of pharmaceutical products. Its products are focused on treating conditions, such as chronic autoimmune diseases in rheumatology, gastroenterology and dermatology; oncology, including blood cancers; virology, including hepatitis C virus (HCV) and human immunodeficiency virus (HIV); neurological disorders, such as Parkinson’s disease and multiple sclerosis; metabolic diseases, including thyroid disease and complications associated with cystic fibrosis, and other serious health conditions.

Receive News & Stock Ratings for AbbVie Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie Inc. and related stocks with our FREE daily email newsletter.